Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701769 | 1.00 | TDO2 (0.41) | TDO2KMOGRM2KDM2BPHF8 | |
| SCHEMBL29989603 | 0.88 | TDO2 (0.41) | TDO2GRM2METAP2CYP2C9SLC9A1 | |
| SCHEMBL31599650 | 0.75 | GRM2 (0.40) | KMOGRM2KDM4EALDH1A1SLC9A1 | |
| SCHEMBL24851097 | 0.73 | HTR2A (0.35) | KMOMETAP2 | |
| SCHEMBL20529676 | 0.72 | TDO2 (0.39) | TDO2METAP2 | |
| SCHEMBL20529711 | 0.72 | MET (0.48) | TDO2 | |
| SCHEMBL30701749 | 0.71 | ALDH1A1 (0.56) | TDO2GRM2KDM4EALDH1A1SLC9A1 | |
| SCHEMBL24024514 | 0.71 | TDO2 (0.42) | TDO2KDM4EALDH1A1 | |
| SCHEMBL20529669 | 0.70 | TDO2 (0.51) | TDO2KMOGRM2SLC9A1 | |
| SCHEMBL6044270 | 0.70 | KDM4C (0.40) | TDO2KMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11731966-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731966-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210355118-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-11-18 | — | — | US | disclosed |
| WO-2018187480-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731966-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | TDO2 4221/4885KMO 2000/4885GRM2 222/4885 |
| US-20210355118-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | TDO2 4221/4885KMO 2000/4885GRM2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.